Carmody, R. and Keeshan, K. (2017) The Tribble with APL: a new road to therapy. Cancer Cell, 31(5), pp. 612-613. (doi: 10.1016/j.ccell.2017.04.011) (PMID:28486101)
|
Text
140027.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 341kB |
Abstract
The t(15;17) translocation generates a PML-RARα fusion protein causative for acute promyelocytic leukemia (APL). Li et al. now identify the pseudokinase stress protein TRIB3 as an important factor in APL disease progression and therapy resistance. Targeting the interaction of TRIB3 and PML-RARα using peptide technology provides a novel therapeutic approach.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Carmody, Dr Ruaidhri and Keeshan, Dr Karen |
Authors: | Carmody, R., and Keeshan, K. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Journal Name: | Cancer Cell |
Publisher: | Elsevier |
ISSN: | 1535-6108 |
ISSN (Online): | 1878-3686 |
Published Online: | 08 May 2017 |
Copyright Holders: | Copyright © 2017 Elsevier Inc. |
First Published: | First published in Cancer Cell 31(5): 612-613 |
Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record